{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:45:15Z","timestamp":1785527115461,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"stichting bergh in het zadel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiosarcoma (AS) is a rare malignancy with a poor prognosis. It can develop spontaneously or due to previous radiotherapy (RT), ultraviolet (UV) radiation, or lymphoedema (Stewart Treves AS). Novel therapeutic approaches are needed, but progress is hindered because of the heterogeneity and rarity of AS. In order to explore the potential of immune checkpoint inhibition (ICI), we investigated the protein expression of programmed cell death 1 (PD-1), programmed death-ligand 1 (PD-L1), and CD8\u2009+\u2009T cells in 165 AS cases in relation to AS subgroups based on clinical classification and in relation to whole-genome methylation profiling based clusters (A1, A2, B1, B2). High PD-L1 and PD-1 expression were predominantly shown in UV-associated, visceral, and soft tissue AS. RT-associated AS showed predominantly high PD-1 expression. CD8\u2009+\u2009T cell infiltration was present in the majority of AS samples. Within the UV-associated AS, two different clusters can be distinguished by DNA methylation profiling. Cases in cluster A1 showed higher PD-1 (<jats:italic>p<\/jats:italic>\u2009=\u20090.015), PD-L1 (<jats:italic>p<\/jats:italic>\u2009=\u20090.015), and CD8\u2009+\u2009T cells (<jats:italic>p<\/jats:italic>\u2009=\u20090.008) compared to those in cluster B2, suggesting that these UV-AS tumors are more immunogenic than B2 tumors showing a difference even within one subgroup. In soft tissue AS, combined PD-1 and PD-L1 expression showed a trend toward poor survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.051), whereas in UV-associated AS, PD-1 expression correlated with better survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.035). In conclusion, we show the presence of PD-1, PD-L1, and CD8\u2009+\u2009T cells in the majority of AS but reveal differences between and within AS subgroups, providing prognostic information and indicating to be predictive for ICI.<\/jats:p>","DOI":"10.1007\/s12026-021-09259-4","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T03:04:52Z","timestamp":1642561492000},"page":"256-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups"],"prefix":"10.1007","volume":"70","author":[{"given":"T.","family":"Tomassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Weidema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H. S.","family":"Hillebrandt-Roeffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"van der Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PALGA group*","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M. E.","family":"Desar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. E.","family":"Flucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-0505","authenticated-orcid":false,"given":"Yvonne M. H.","family":"Versleijen-Jonkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"9259_CR1","first-page":"2303","volume":"9","author":"J Cao","year":"2019","unstructured":"Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res. 2019;9:2303\u201313.","journal-title":"Am J Cancer Res"},{"key":"9259_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11864-018-0531-3","volume":"19","author":"V Florou","year":"2018","unstructured":"Florou V, Wilky BA. Current and Future Directions for Angiosarcoma Therapy. Curr Treat Options Oncol. 2018;19:14.","journal-title":"Curr Treat Options Oncol"},{"key":"9259_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(10)70023-1","volume":"11","author":"RJ Young","year":"2010","unstructured":"Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11:983\u201391.","journal-title":"Lancet Oncol"},{"key":"9259_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","volume":"56","author":"A Kollar","year":"2017","unstructured":"Kollar A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litiere S, Marreaud S, Gronchi A, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol. 2017;56:88\u201392.","journal-title":"Acta Oncol"},{"key":"9259_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/JEP.S146211","volume":"10","author":"MJ Wagner","year":"2018","unstructured":"Wagner MJ, Cranmer LD, Loggers ET, Pollack SM. Propranolol for the treatment of vascular sarcomas. J Exp Pharmacol. 2018;10:51\u20138.","journal-title":"J Exp Pharmacol"},{"key":"9259_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00130404-200505000-00011","volume":"11","author":"MG Fury","year":"2005","unstructured":"Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241\u20137.","journal-title":"Cancer J"},{"key":"9259_CR7","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1093\/annonc\/mdm381","volume":"18","author":"J Fayette","year":"2007","unstructured":"Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S, Ranchere D, Pouillart P, Coindre JM, Blay JY. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18:2030\u20136.","journal-title":"Ann Oncol"},{"key":"9259_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12916-017-0831-7","volume":"15","author":"M Savina","year":"2017","unstructured":"Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, Cousin S, Terrier P, Ranchere-Vince D, Meeus P, Stoeckle E, Honore C, Sargos P, Sunyach MP, Le Pechoux C, Giraud A, Bellera C, Le Loarer F, Italiano A. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15:78.","journal-title":"BMC Med"},{"key":"9259_CR9","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767\u201378.","journal-title":"N Engl J Med"},{"key":"9259_CR10","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/cas.13981","volume":"110","author":"A Kawamura","year":"2019","unstructured":"Kawamura A, Kawamura T, Riddell M, Hikita T, Yanagi T, Umemura H, Nakayama M. Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda\/iota in cutaneous angiosarcoma. Cancer Sci. 2019;110:1780\u20139.","journal-title":"Cancer Sci"},{"key":"9259_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0000000000000317","volume":"43","author":"T Gambichler","year":"2020","unstructured":"Gambichler T, Koim S, Wrobel M, Kafferlein HU, Bruning T, Stockfleth E, Becker JC, Lang K. Expression of programmed cell death proteins in Kaposi sarcoma and cutaneous angiosarcoma. J Immunother. 2020;43:169\u201374.","journal-title":"J Immunother"},{"key":"9259_CR12","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/ijc.28581","volume":"134","author":"H Fujii","year":"2014","unstructured":"Fujii H, Arakawa A, Utsumi D, Sumiyoshi S, Yamamoto Y, Kitoh A, Ono M, Matsumura Y, Kato M, Konishi K, Shiga T, Sano S, Sakaguchi S, Miyagawa-Hayashino A, Takahashi K, Uezato H, Miyachi Y, Tanioka M. CD8(+) tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int J Cancer. 2014;134:2393\u2013402.","journal-title":"Int J Cancer"},{"key":"9259_CR13","doi-asserted-by":"publisher","first-page":"e1253657","DOI":"10.1080\/2162402X.2016.1253657","volume":"6","author":"Y Honda","year":"2017","unstructured":"Honda Y, Otsuka A, Ono S, Yamamoto Y, Seidel JA, Morita S, Hirata M, Kataoka TR, Takenouchi T, Fujii K, Kanekura T, Okubo Y, Takahashi K, Yanagi T, Hoshina D, Hata H, Abe R, Fujimura T, Funakoshi T, Yoshino K, Masuzawa M, Amoh Y, Tanaka R, Fujisawa Y, Honda T, Kabashima K. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology. 2017;6:e1253657.","journal-title":"Oncoimmunology"},{"issue":"4","key":"9259_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1200\/JGO.2016.005843","volume":"3","author":"A Shimizu","year":"2016","unstructured":"Shimizu A, Kaira K, Okubo Y, Utsumi D, Yasuda M, Asao T, Nishiyama M, Takahashi K, Ishikawa O. Positive PD-L1 expression predicts worse outcome in cutaneous angiosarcoma. J Glob Oncol. 2016;3(4):360\u20139.","journal-title":"J Glob Oncol"},{"key":"9259_CR15","doi-asserted-by":"publisher","first-page":"8141056","DOI":"10.1155\/2018\/8141056","volume":"2018","author":"SP Bagaria","year":"2018","unstructured":"Bagaria SP, Chang YH, Gray RJ, Ashman JB, Attia S, Wasif N. Improving long-term outcomes for patients with extra-abdominal soft tissue sarcoma regionalization to high-volume centers, improved compliance with guidelines or both? Sarcoma. 2018;2018:8141056.","journal-title":"Sarcoma"},{"key":"9259_CR16","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.7150\/jca.19060","volume":"8","author":"G Botti","year":"2017","unstructured":"Botti G, Scognamiglio G, Marra L, Pizzolorusso A, Di Bonito M, De Cecio R, Cantile M, De Chiara A. Programmed death ligand 1 (PD-L1) expression in primary angiosarcoma. J Cancer. 2017;8:3166\u201372.","journal-title":"J Cancer"},{"key":"9259_CR17","doi-asserted-by":"crossref","unstructured":"Googe PB, Flores K, Jenkins F, Merritt B, Moschos SJ, Grilley-Olson JE. Immune checkpoint markers in superficial angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and tumor-infiltrating lymphocytes. Am J Dermatopathol. 2020.","DOI":"10.1097\/DAD.0000000000001843"},{"issue":"3","key":"9259_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","volume":"46","author":"SP D'Angelo","year":"2015","unstructured":"D\u2019Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, Tap WD. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357\u201365.","journal-title":"Hum Pathol"},{"key":"9259_CR19","doi-asserted-by":"publisher","first-page":"e82870","DOI":"10.1371\/journal.pone.0082870","volume":"8","author":"JR Kim","year":"2013","unstructured":"Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, Kang MJ, Jang KY. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e82870.","journal-title":"PLoS One"},{"key":"9259_CR20","doi-asserted-by":"publisher","first-page":"e1389366","DOI":"10.1080\/2162402X.2017.1389366","volume":"7","author":"M Boxberg","year":"2018","unstructured":"Boxberg M, Steiger K, Lenze U, Rechl H, von Eisenhart-Rothe R, Wortler K, Weichert W, Langer R, Specht K. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy. Oncoimmunology. 2018;7:e1389366.","journal-title":"Oncoimmunology"},{"key":"9259_CR21","first-page":"192","volume":"1","author":"K Kosemehmetoglu","year":"2017","unstructured":"Kosemehmetoglu K, Ozogul E, Babaoglu B, Tezel GG, Gedikoglu G. Programmed death ligand 1 (PD-L1) expression in malignant mesenchymal tumors. Turk Patoloji Derg. 2017;1:192\u20137.","journal-title":"Turk Patoloji Derg"},{"key":"9259_CR22","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.7150\/jca.18683","volume":"8","author":"Y Que","year":"2017","unstructured":"Que Y, Xiao W, Guan YX, Liang Y, Yan SM, Chen HY, Li QQ, Xu BS, Zhou ZW, Zhang X. PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer. 2017;8:2018\u201325.","journal-title":"J Cancer"},{"key":"9259_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s13402-020-00496-7","volume":"43","author":"NC Blessin","year":"2020","unstructured":"Blessin NC, Spriestersbach P, Li W, Mandelkow T, Dum D, Simon R, Hube-Magg C, Lutz F, Viehweger F, Lennartz M, Fraune C, Nickelsen V, Fehrle W, Gobel C, Weidemann S, Clauditz T, Lebok P, Moller K, Steurer S, Izbicki JR, Sauter G, Minner S, Jacobsen F, Luebke AM, Buscheck F, Hoflmayer D, Wilczak W, Burandt E, Hinsch A. Prevalence of CD8(+) cytotoxic lymphocytes in human neoplasms. Cell Oncol (Dordr). 2020;43:421\u201330.","journal-title":"Cell Oncol (Dordr)"},{"key":"9259_CR24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00262-020-02552-5","volume":"69","author":"MF Orth","year":"2020","unstructured":"Orth MF, Buecklein VL, Kampmann E, Subklewe M, Noessner E, Cidre-Aranaz F, Romero-Perez L, Wehweck FS, Lindner L, Issels R, Kirchner T, Altendorf-Hofmann A, Grunewald TGP, Knosel T. A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. Cancer Immunol Immunother. 2020;69:1353\u201362.","journal-title":"Cancer Immunol Immunother"},{"key":"9259_CR25","doi-asserted-by":"publisher","first-page":"e0222551","DOI":"10.1371\/journal.pone.0222551","volume":"15","author":"AC Vargas","year":"2020","unstructured":"Vargas AC, Maclean FM, Sioson L, Tran D, Bonar F, Mahar A, Cheah AL, Russell P, Grimison P, Richardson L, Gill AJ. Prevalence of PD-L1 expression in matched recurrent and\/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. PLoS One. 2020;15:e0222551.","journal-title":"PLoS One"},{"issue":"5","key":"9259_CR26","doi-asserted-by":"publisher","first-page":"FSO691","DOI":"10.2144\/fsoa-2020-0211","volume":"7","author":"JB Lee","year":"2021","unstructured":"Lee JB, Ahn BC, Kim SH, Lee YH, Han JW, Jeon MK, Kim SH, Kim HS. Prognostic implications of PD-L1 expression in patients with angiosarcoma. Future Sci OA. 2021;7(5):FSO691.","journal-title":"Future Sci OA"},{"key":"9259_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","volume":"7","author":"V Florou","year":"2019","unstructured":"Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, Castle JC, Buell JS, Trent JC, Wilky BA. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019;7:213.","journal-title":"J Immunother Cancer"},{"key":"9259_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40425-017-0263-0","volume":"5","author":"S Sindhu","year":"2017","unstructured":"Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. J Immunother Cancer. 2017;5:58.","journal-title":"J Immunother Cancer"},{"key":"9259_CR29","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2217\/imt-2020-0122","volume":"12","author":"F Xu","year":"2020","unstructured":"Xu F, Zheng J, Fu M, Zhou H. Antiprogrammed cell death protein 1 immunotherapy for angiosarcoma with high programmed death-ligand 1 expression: a case report. Immunotherapy. 2020;12:771\u20136.","journal-title":"Immunotherapy"},{"key":"9259_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00107","volume":"2","author":"R Hamacher","year":"2018","unstructured":"Hamacher R, Kampfe D, Reuter-Jessen K, Pottgen C, Podleska LE, Farzaliyev F, Steinau HU, Schuler M, Schildhaus HU, Bauer S. dramatic response of a PD-L1-positive advanced angiosarcoma of the scalp to pembrolizumab. Jco Precis Oncol. 2018;2:1\u20137.","journal-title":"Jco Precis Oncol"},{"key":"9259_CR31","doi-asserted-by":"crossref","unstructured":"Momen S, Fassihi H, Davies HR, Nikolaou C, Degasperi A, Stefanato CM, Dias JML, Dasgupta D, Craythorne E, Sarkany R, Papa S, Nik-Zainal S. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Csh Mol Case Stud. 2019;5.","DOI":"10.1101\/mcs.a004408"},{"key":"9259_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","volume":"26","author":"CA Painter","year":"2020","unstructured":"Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, Damon AL, Shah S, Kim D, Gomez Tejeda Zanudo J, Hornick JL, Chen YL, Merriam P, Raut CP, Demetri GD, Van Tine BA, Lander ES, Golub TR, Wagle N. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020;26:181\u20137.","journal-title":"Nat Med"},{"issue":"93","key":"9259_CR33","first-page":"100","volume":"26","author":"ME Weidema","year":"2020","unstructured":"Weidema ME, van de Geer E, Koelsche C, Desar IME, Kemmeren P, Hillebrandt-Roeffen MHS, Ho VKY, van der Graaf WTA, Versleijen-Jonkers YMH, von Deimling A, Flucke UE, PGroup. DNA methylation profiling identifies distinct clusters in angiosarcomas. Clin Cancer Res. 2020;26(93):100.","journal-title":"Clin Cancer Res"},{"key":"9259_CR34","first-page":"19","volume":"29","author":"M Casparie","year":"2007","unstructured":"Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29:19\u201324.","journal-title":"Cell Oncol"},{"key":"9259_CR35","doi-asserted-by":"crossref","unstructured":"Weidema ME, Flucke UE, van der Graaf WTA, Ho VKY, Hillebrandt-Roeffen MHS, Dutch Nationwide N, Registry of H, Cytopathology G, Versleijen-Jonkers YMH, Husson O, Desar IME. Prognostic Factors in a Large nationwide cohort of histologically confirmed primary and secondary angiosarcomas. Cancers (Basel). 2019;11.","DOI":"10.3390\/cancers11111780"},{"key":"9259_CR36","doi-asserted-by":"publisher","first-page":"71371","DOI":"10.18632\/oncotarget.19071","volume":"8","author":"AEM van Erp","year":"2017","unstructured":"van Erp AEM, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, van Houdt L, Gorris MAJ, van Dam LS, Mentzel T, Weidema ME, Savci-Heijink CD, Desar IME, Merks HHM, van Noesel MM, Shipley J, van der Graaf WTA, Flucke UE, Meyer-Wentrup FAG. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent. Oncotarget. 2017;8:71371\u201384.","journal-title":"Oncotarget"},{"key":"9259_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.lungcan.2015.05.007","volume":"89","author":"WA Cooper","year":"2015","unstructured":"Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O\u2019Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung cancer (Amsterdam, Netherlands). 2015;89:181\u20138.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"9259_CR38","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","volume":"20","author":"KA Schalper","year":"2014","unstructured":"Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20:2773\u201382.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"9259_CR39","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1172\/JCI139080","volume":"130","author":"JY Chan","year":"2020","unstructured":"Chan JY, Lim JQ, Yeong J, Ravi V, Guan P, Boot A, Tay TKY, Selvarajan S, Md Nasir ND, Loh JH, Ong CK, Huang D, Tan J, Li Z, Ng CC, Tan TT, Masuzawa M, Sung KW, Farid M, Quek RHH, Tan NC, Teo MCC, Rozen SG, Tan P, Futreal A, Teh BT, Soo KC. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. J Clin Invest. 2020;130(11):5833\u201346.","journal-title":"J Clin Invest"},{"key":"9259_CR40","doi-asserted-by":"crossref","unstructured":"Starzer AM, Berghoff AS, Hamacher R, Tomasich E, Feldmann K, Hatziioannou T, Traint S, Lamm W, Noebauer-Huhmann IM, Furtner J, Mullauer L, Amann G, Bauer S, Schildhaus HU, Preusser M, Heller G, Brodowicz T. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. J Immunother Cancer. 2021;9.","DOI":"10.1136\/jitc-2020-001458"},{"key":"9259_CR41","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","volume":"11","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, Meylan M, de Reynies A, Sautes-Fridman C, Fridman WH. The Tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020;11:784.","journal-title":"Front Immunol"},{"key":"9259_CR42","first-page":"S106","volume":"27","author":"DE Meyers","year":"2020","unstructured":"Meyers DE, Banerji S. Biomarkers of immune checkpoint inhibitor efficacy in cancer. Curr Oncol. 2020;27:S106\u201314.","journal-title":"Curr Oncol"},{"key":"9259_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reynies A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougouin A, Moreira M, Lacroix G, Natario I, Adam J, Lucchesi C, Laizet YH, Toulmonde M, Burgess MA, Bolejack V, Reinke D, Wani KM, Wang WL, Lazar AJ, Roland CL, Wargo JA, Italiano A, Sautes-Fridman C, Tawbi HA, Fridman WH. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577:556\u201360.","journal-title":"Nature"},{"key":"9259_CR44","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1002\/ctm2.118","volume":"10","author":"J Li","year":"2020","unstructured":"Li J, Wei Q, Wu X, Sima J, Xu Q, Wu M, Wang F, Mou H, Hu H, Zhao J, Li D, Hu J, Zhang L, Zhu X, Chen L, Luo C, Yan J, He J, Ma Y, Shao Y, Wu W, Ying J. Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response. Clin Transl Med. 2020;10:e118.","journal-title":"Clin Transl Med"},{"key":"9259_CR45","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"9259_CR46","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"9259_CR47","doi-asserted-by":"publisher","first-page":"e0231936","DOI":"10.1371\/journal.pone.0231936","volume":"15","author":"M Zajac","year":"2020","unstructured":"Zajac M, Ye J, Mukhopadhyay P, Jin X, Ben Y, Antal J, Gupta AK, Rebelatto MC, Williams JA, Walker J. Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. PLoS One. 2020;15:e0231936.","journal-title":"PLoS One"},{"key":"9259_CR48","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00292-018-0507-x","volume":"39","author":"HU Schildhaus","year":"2018","unstructured":"Schildhaus HU. Predictive value of PD-L1 diagnostics. Pathologe. 2018;39:498\u2013519.","journal-title":"Pathologe"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-021-09259-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T15:20:40Z","timestamp":1726500040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-021-09259-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["9259"],"URL":"https:\/\/doi.org\/10.1007\/s12026-021-09259-4","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"assertion":[{"value":"20 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was obtained from the local certified Medical Ethics Committee of the Radboudumc, Nijmegen, The Netherlands (file number 2016\u20132686).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}